Milvexian

Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA.

The European Society of Cardiology Congress was held Aug. 26 to 29 in Barcelona, Spain, and online, having an in-person component for the first time since 2019.